From: Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia
Demographics | Non-TXA Group (N = 18) | TXA Group (N = 16) | p Value |
---|---|---|---|
Agea (yr) | 37.2 ± 11.8 | 38.9 ± 11.3 | 0.681 |
Sexb (male/female) | 18/0 | 16/0 | 1.000 |
BMIa (kg/m2) | 23.2 ± 5.8 | 23.4 ± 2.4 | 0.941 |
Severityb | Â | Â | 0.597 |
 mild | 2 | 1 | |
 moderate | 6 | 8 | |
 severe | 10 | 7 | |
Jointsb | Â | Â | 0.957 |
 Unilateral TKA | 8 | 6 | |
 Unilateral THA | 6 | 6 | |
 Simultaneous TKA | 2 | 3 | |
 Simultaneous THA | 2 | 1 | |
Hba (g/L) | 129.2 ± 12.3 | 128.0 ± 10.0 | 0.765 |
Hcta (%) | 0.40 ± 0.04 | 0.40 ± 0.03 | 0.819 |
Platelet counta (× 109/L) | 138 ± 44 | 149 ± 58 | 0.561 |
INRa | 0.99 ± 0.97 | 1.00 ± 0.10 | 0.891 |
APTTa (sec) | 92.3 ± 26.1 | 92.4 ± 21.5 | 0.986 |
Preoperative FVIII activitya (%) | 2.13 ± 1.12 | 2.27 ± 1.06 | 0.72 |
VAS scorea (0–10, 10 worst) | 4.5 ± 1.10 | 4.75 ± 1.48 | 0.578 |
FVIII inhibitorb (negative/positive) | 5/13 | 6/10 | 0.717 |
Knee | N = 12 | N = 12 |  |
 ROMa (Flexion/Extension) (°) | 52 ± 23 | 49 ± 20 | 0.779 |
 KSS scorea | 33 ± 20 | 30 ± 19 | 0.679 |
Hip | N = 10 | N = 8 |  |
 ROM Flexion/Extensiona (°) | 59 ± 21 | 62 ± 20 | 0.768 |
 ROM Internal−/External-Rotaa (°) | 17 ± 4 | 15 ± 8 | 1.000 |
 ROM Adduction/Abductiona (°) | 28 ± 20 | 23 ± 18 | 0.555 |
HHS scorea | 35 ± 15 | 31 ± 14 | 0.543 |